Ocular Therapeutix
OCUL
140 hedge funds and large institutions have $288M invested in Ocular Therapeutix in 2021 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 51 increasing their positions, 42 reducing their positions, and 28 closing their positions.
21% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 42
0% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 28
1% less funds holding
Funds holding: 141 → 140 (-1)
3% less call options, than puts
Call options by funds: $2.1M | Put options by funds: $2.17M
3.95% less ownership
Funds ownership: 58.16% → 54.21% (-3.9%)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
35% less capital invested
Capital invested by funds: $445M → $288M (-$157M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$11.6M |
| 2 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
+$4.83M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.06M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$1.92M |
| 5 |
Voloridge Investment Management
Jupiter,
Florida
|
+$1.88M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$11.4M |
| 2 |
AAA
Affinity Asset Advisors
New York
|
-$7.5M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$7.5M |
| 4 |
KCM
Kornitzer Capital Management
Shawnee Mission,
Kansas
|
-$6.78M |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$3.92M |
OCUL Hedge Fund Activity: Q4 2021 in Review
140 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Ocular Therapeutix (OCUL) for Q4 2021, worth a combined $288M — down 35% from $445M a quarter earlier.
Fund positioning in OCUL was balanced in Q4 2021: 28 funds opened new positions, 28 closed out, 51 added to existing stakes and 42 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $11.6M. The largest seller was Fidelity Investments, exiting entirely with an estimated $11.4M sold.
- 140 institutional investors held Ocular Therapeutix (OCUL) as of Q4 2021, down from 141 in Q3 2021.
- Funds reported $288M of Ocular Therapeutix stock for Q4 2021, down 35% quarter-over-quarter.
- 28 funds opened new Ocular Therapeutix positions in Q4 2021 and 28 closed out, a net change of 0 holders.
- The largest Ocular Therapeutix buyer in Q4 2021 was Citadel Advisors, an estimated $11.6M added.
- The largest Ocular Therapeutix seller in Q4 2021 was Fidelity Investments, an estimated $11.4M sold.
Based on aggregated 13F filings for Q4 2021.